title: New developments in the pharmacologic treatment of obesity.
abstract: Obesity, defined as a body mass index (BMI, kg/m(2) ) >30, is a significant public health problem. It's estimated that 50 percent of the U.S. population will be classified as obese by the year 2030. Due to associated health complications and rising health care costs related to obesity, new treatment options are being explored. For people who need additional treatment beyond lifestyle modification, new pharmacologic options have been developed that may assist in reducing BMI. Health care providers and patients should consider each person's individual health history and consider both the potential risks and benefits of these therapies.
authors: Department of Nursing, School of Health and Environment, University of Massachusetts, Lowell, MA, USA. Heidi_Fantasia@uml.edu
authors: Heidi Collins
authors: HC
authors: Fantasia
mesh_terms: D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001552:Benzazepines / Q000494:pharmacology / Q000627:therapeutic use*; D015992:Body Mass Index; D004338:Drug Combinations; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008019:Life Style; D009765:Obesity / Q000188:drug therapy* / Q000451:nursing; D010645:Phentermine / Q000494:pharmacology / Q000627:therapeutic use*; D011247:Pregnancy; D018570:Risk Assessment; D014481:United States
chemical_list: D019440:Anti-Obesity Agents; D001552:Benzazepines; D004338:Drug Combinations; C576188:Qsymia; D005632:Fructose; C506658:lorcaserin; D010645:Phentermine